Brevan Howard Capital Management LP Has $1.15 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Brevan Howard Capital Management LP raised its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 210.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,539 shares of the company's stock after buying an additional 30,213 shares during the period. Brevan Howard Capital Management LP owned 0.05% of IDEAYA Biosciences worth $1,145,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in IDEAYA Biosciences in the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after acquiring an additional 853 shares during the last quarter. KBC Group NV lifted its stake in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after acquiring an additional 1,923 shares during the period. Cibc World Markets Corp bought a new position in IDEAYA Biosciences in the fourth quarter valued at about $203,000. Finally, Mariner LLC increased its position in IDEAYA Biosciences by 9.8% in the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares during the period. 98.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on IDYA shares. Stephens reaffirmed an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Stock Down 4.5 %

IDYA traded down $0.81 during trading on Friday, hitting $17.37. The company had a trading volume of 1,191,762 shares, compared to its average volume of 990,259. The company has a market capitalization of $1.52 billion, a PE ratio of -5.26 and a beta of 0.26. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42. The firm's 50-day moving average price is $17.74 and its 200 day moving average price is $22.64.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the company earned ($0.53) EPS. Sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.